VistaGen Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.05.23	Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health (Businesswire)
19.04.23	Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference (Businesswire)
06.04.23	Vistagen Receives New European Patent for AV-101 (Businesswire)
22.03.23	Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder (Businesswire)
08.03.23	Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder (Businesswire)
02.03.23	Vistagen to Present at Cowen 43rd Annual Health Care Conference (Businesswire)
01.03.23	Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine (Businesswire)
07.02.23	Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results (Businesswire)
07.02.23	Ausblick: VistaGen Therapeutics stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
06.02.23	Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 (Businesswire)
02.02.23	Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition (Businesswire)
24.01.23	Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder (Businesswire)
10.01.23	Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety (Businesswire)
30.12.22	Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder (Businesswire)
21.12.22	Vistagen to Acquire Pherin Pharmaceuticals (Businesswire)
06.12.22	Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder (Businesswire)
30.11.22	Vistagen Receives FDA "Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder (Businesswire)
17.11.22	Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease (Businesswire)
10.11.22	Vistagen Reports Second Quarter Financial Results and Provides Corporate Update (Businesswire)
09.11.22	Ausblick: VistaGen Therapeutics legt Quartalsergebnis vor (finanzen.net)
04.11.22	Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022 (Businesswire)
03.11.22	Vistagen to Present at Stifel 2022 Healthcare Conference (Businesswire)
26.10.22	Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ (Businesswire)
19.10.22	Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022 (Businesswire)
03.10.22	Vistagen to Participate at Cantor Neurology & Psychiatry Conference (Businesswire)
20.09.22	Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit (Businesswire)
19.09.22	Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects (Businesswire)
09.09.22	Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences (Businesswire)
08.09.22	Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis (Businesswire)
11.08.22	VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update (Businesswire)
10.08.22	Ausblick: VistaGen Therapeutics vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
09.08.22	VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022 (Businesswire)
22.07.22	VistaGen : Phase 3 Trial Of PH94B In Social Anxiety Disorder Fails To Meet Primary Endpoint (RTTNews)
22.07.22	VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B (Businesswire)
12.07.22	VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit (Businesswire)
07.07.22	VistaGen to Participate at William Blair Biotech Focus Conference 2022 (Businesswire)
23.06.22	VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update (Businesswire)
22.06.22	VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder (Businesswire)
22.06.22	Ausblick: VistaGen Therapeutics legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
09.02.22	Ausblick: VistaGen Therapeutics präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
09.11.21	Ausblick: VistaGen Therapeutics zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
30.06.21	VistaGen To Report Phase 3 Data From Social Anxiety Disorder Trial In Mid-2022 (RTTNews)
19.02.21	Will SAD Trial Make VistaGen Investors Happy? (RTTNews)
19.02.21	FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLY (RTTNews)
03.08.20	Pre-market Movers In Healthcare Sector: IMUX, TRVN, VAR, VTGN… (RTTNews)
27.05.20	VistaGen, Nuformix Enter Collaboration In CNS Therapeutics - Quick Facts (RTTNews)
18.05.20	VistaGen Submits PH94B Phase 2A Study Protocol To FDA - Quick Facts (RTTNews)
28.04.20	VistaGen Expands PH94B Trial To Include Adjustment Disorder Related To COVID-19 (RTTNews)
14.11.19	VistaGen Says Disappointed With Phase 2 Results On Major Depressive Disorder (RTTNews)
04.10.18	VTVT Abuzz, TRVN Faces FDA Panel Next Week, BLRX Awaits Data In Oct. (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu VistaGen Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten